The role of interleukin-1β in type 2 diabetes mellitus: A systematic review and meta-analysis

Type 2 diabetes mellitus (T2DM) is a multifactorial non-communicable disease that is characterized by insulin resistance and chronic sub-clinical inflammation. Among the emerging inflammatory markers observed to be associated with beta-cell damage is interleukin 1 beta (IL1 beta), a proinflammatory cytokine that modulates important metabolic processes including insulin secretion and beta-cell apoptosis. The present systematic review and meta-analysis gathers available evidence on the emerging role of IL1 beta in T2DM. PubMed and Embase were searched for human studies that assessed 1L1 beta in T2DM individuals from 2016-2021. Thirteen studies (N=2680; T2DM=1182, controls=1498) out of 523 were included in the systematic review and only 3 studies in the meta-analysis. Assays were the most commonly used quantification method and lipopolysaccharides as the most common stimulator for IL1 beta upregulation. Random and fixed effects meta-analysis showed non-significant mean differences of IL1 beta concentrations between the T2DM and controls. Given the high heterogeneity and small subset of studies included, caution is advised in the interpretation of results. The present systematic review and meta-analysis highlights the limited evidence available that could implicate 1L1 beta as a potent biomarker for T2DM. Standardization of 1L1 beta assays with larger sample sizes are encouraged in future observational and prospective studies.

Automated summary

This systematic review and meta-analysis examines the emerging role of interleukin 1 beta (IL1 beta) in type 2 diabetes mellitus (T2DM). The results indicate that there is no significant difference in IL1 beta concentrations between T2DM patients and controls. The study highlights the limited evidence available and emphasizes the need for larger sample sizes and standardized assays in future research.